(2'R,9S)-7-(4-chlorophenyl)-2'-(methoxymethyl)-4,5,13-trimethylspiro[3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene-9,1'-cyclopropane] → (1R,2S)-4'-(4-chlorophenyl)-2,2',3',9'-tetramethylspiro-[cyclopropane-1,6'-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine]

Participants

Reaction Steps

A procedure analogous to that set forth for Compound 202 was followed, with the exception that (1R,2S)-5′-(4-chlorophenyl)-2,6′,7′-trimethylspiro[cyclopropane-1,3′-thieno[2,3-e][1,4]diazepin]-2′(1′H)-one (Compound 218) was used as starting material. LRMS (M+H)+: 383 m/z. 1H NMR (400 MHz, DMSO-d6) δ 7.50 (s, 4H), 2.56-2.62 (m, 3H), 2.39 (s, 3H), 1.94-2.05 (m, 1H), 1.58 (s, 3H), 1.39 (d, J=6.18 Hz, 1H), 1.10 (s, 1H), 0.79 (d, J=5.49 Hz, 3H).

Provenance & Evidence